L-thyroxine

ApprovedSmall molecule

SShandong Provincial Hospital

L-thyroxine is one of 52 small molecule programs targeting Hypothyroidism. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypothyroidismActive, not recruiting

AtherosclerosisActive, not recruiting

HypothyroidismApproved

Active, not recruiting

AtherosclerosisApproved

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Atherosclerosis

#DrugCompanyPhaseTrials

Avandia

Alnylam Pharmaceuticals

Phase 3

3 2

Depo-Provera

Pfizer

Phase 3

2 3

Estrace

Novo Nordisk

Phase 3

2 4

Actemra

Roche

Phase 3

1 5

Colcrys

Alnylam Pharmaceuticals

Phase 3

1 6

Glucotrol

Pfizer

Phase 3

1 7

Brilinta

AstraZeneca

Phase 3

1 8

Ilaris

Novartis

Phase 3

—9

Benicar

CCosette Pharmaceuticals, Inc.

Phase 3

2 10

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypothyroidism3 trials

Levothyroxine Treatment on Cardiac Function in Children With Subclinical Hypothyroidism

Recruiting·TTanta University·N/A·NCT07393165·40 enrolled

Neurocognitive and Metabolic Effects of Mild Hypothyroidism

Completed·OOregon Health and Science University·Phase 4·NCT00565864·173 enrolled

Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism

Unknown status·MMeyer Children's Hospital IRCCS·Phase 4·NCT02917863·70 enrolled

Atherosclerosis2 trials

Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism

Unknown status·SShandong Provincial Hospital·Phase 4·NCT01848171·700 enrolled

Effect of L-Thyroxine on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism

Unknown status·SShandong Provincial Hospital·Phase 4·NCT01831869·400 enrolled

Cardiac Surgery1 trial

Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery

Completed·—·Phase 3·NCT06660823·70 enrolled

Newborns1 trial

L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia

Completed·—·Phase 3·NCT01306227·50 enrolled

Thyroid1 trial

Metabolic Changes in Hypothyroid Patients

Completed·UUniversity of Aarhus·N/A·NCT00524238·22 enrolled

1 more indication

Bipolar Depression1 trial

Supraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression

Completed·—·Phase 2/3·NCT01528839·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for L-thyroxine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L-thyroxine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L-thyroxine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Provincial Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SShandong Provincial Hospital

L-thyroxine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypothyroidism3 trials

Atherosclerosis2 trials

Cardiac Surgery1 trial

Newborns1 trial

Thyroid1 trial

Bipolar Depression1 trial

References

Drug Info

Quick Facts

Related News